SawsanRashdanMD

PubMed

• A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer.
  Madeleine B Hopson, Sawsan Rashdan> ;Frontiers in Oncology. 2024 Jan 1
• Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors.
  Mundra, V., Yang, Y., von Itzstein, M., Fattah, F., Gonugunta, A., Hannan, R., Pop, L., Zhang, Y., Wang, Y., Sheffield, T., Xie, Y., Dowell, J., Homsi, J., Rashdan, S....> ;Translational Oncology. 2023 Aug 1
• 2 citations
  The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer.
  Anjali Kalra, Sawsan Rashdan> ;Frontiers in Oncology. 2023 Jan 1
• 4 citations
  Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era.
  Mitchell S Von Itzstein, David Hsiehchen, Tri Le, Sawsan Rashdan, Hui Yang, Christopher Selby, Carlos Alvarez, David E Gerber, Gonugunta, A.> ;Clinical Lung Cancer. 2023 Jan 1
• 3 citations
  Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials.
  Matthew Perez, Caitlin C Murphy, Sandi L Pruitt, Sawsan Rashdan, Asal Rahimi, David E Gerber> ;Journal of the National Comprehensive Cancer Network. 2022 Jul 1
• 7 citations
  Humoral and cellular correlates of a novel immune-related adverse event and its treatment.
  Mitchell S von Itzstein, Hong Mu-Mosley, Farjana Fattah, J David Farrar, Angela Mobely, Sawsan Rashdan, Sunny Lai, Salman F Bhai, Bonnie L Bermas, David Karp, Quan-Zhe...> ;Journal for Immunotherapy of Cancer. 2021 Dec 1
• 1 citations
  Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer
  Sawsan Rashdan, Puneeth Iyengar, John D. Minna, David E. Gerber> ;Translational Lung Cancer Research. 2021 Jul 1
• 5 citations
  Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials
  Sawsan Rashdan, Hui Yang, Tri Le, Christopher Selby, David E. Gerber, Carlos A. Alvarez> ;Clinical Drug Investigation. 2021 Jan 8
• 2 citations
  Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
  Michael Burke, Sawsan Rashdan> ;Frontiers in Oncology. 2021 Sep 30
• 3 citations
  QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.
  Tri Le, Hui Yang, Sawsan Rashdan, Mark S. Link, Vlad G. Zaha, Carlos A. Alvarez, David E. Gerber> ;Clinical Lung Cancer. 2020 Jan 1
• 13 citations
  Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice
  Sawsan Rashdan, David E. Gerber> ;Translational Lung Cancer Research. 2019 Jun 1
• 50 citations
  Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.
  Sawsan Rashdan, John D. Minna, David E. Gerber> ;The Lancet. Respiratory Medicine. 2018 Jun 1
• 7 citations
  A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
  Sawsan Rashdan, David E. Gerber> ;Translational Cancer Research. 2017 Feb 1
• 8 citations
  Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.
  Sawsan Rashdan, David E. Gerber> ;Annals of Translational Medicine. 2016 Dec 1
• 20 citations
  Salvage Therapy for Patients With Germ Cell Tumor
  Sawsan Rashdan, Lawrence H. Einhorn> ;Journal of Oncology Practice. 2016 Sep 21
• 8 citations
  Nintedanib for the treatment of non-small-cell lung cancer
  Sawsan Rashdan, Nasser H. Hanna> ;Expert Opinion on Pharmacotherapy. 2014 Mar 11
• Join now to see all